Intranasal Desmopressin vs IV Ketorolac in Renal Colic Pain Control

NCT ID: NCT02937896

Last Updated: 2016-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is the comparison of efficacy of intravenous ketorolac and intranasal desmopressin in renal colic patients pain control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

40 renal colic patients have been divided into 2 groups randomly, one group has been received 30mg intravenous Ketorolac and 4 puffs nasal Normal Saline while other has been received 40 micrograms nasal Desmopressin and 1cc intravenous Normal Saline. Pain Score before drug administration,also 10, 30 and 60 minutes after drug administration has been measured bye Visual Analogue Scale ( VAS ).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Colic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketorolac

30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.

Group Type EXPERIMENTAL

Ketorolac

Intervention Type DRUG

30mg intravenous Ketorolac.

Normal Saline

Intervention Type DRUG

4 puffs nasal Normal Saline.

Desmopressin

40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous

Group Type ACTIVE_COMPARATOR

Desmopressin

Intervention Type DRUG

40 micrograms Nasal Desmopressin.

Normal Saline

Intervention Type DRUG

1cc intravenous Normal Saline.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Desmopressin

40 micrograms Nasal Desmopressin.

Intervention Type DRUG

Ketorolac

30mg intravenous Ketorolac.

Intervention Type DRUG

Normal Saline

1cc intravenous Normal Saline.

Intervention Type DRUG

Normal Saline

4 puffs nasal Normal Saline.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ddavp Toradol NaCl NaCl

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* renal colic patients

Exclusion Criteria

* history of hypertension and cardiac disease
* pregnant patients
* use of analgesic within 4 hours before intervention
Minimum Eligible Age

16 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shahid Beheshti University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kambiz Nasiri

Emergency Medicine Resident

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

688

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dex as Analgesic Adjuvant in OSA Patients
NCT03613558 WITHDRAWN PHASE1/PHASE2